Greetings SAVE THE DATE: Patient Seminar 29 November, 5:30 – 7.30pm I’m delighted to advise that Dr Henry Chan from North Shore Hospital has agreed...
Myeloma NZ
Daratumumab approved for use on NHS in Scotland
Patients in Scotland will now be able to access the new myeloma treatment, daratumumab (Darzalex®) on the NHS, after the Scottish Medicines...
Article of the Week: Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis
For this week's Article of the Week, we look at an article that describes a review of patient data from the Mayo Clinic. The study sought to...
Research Review: Multiple Myeloma – Issue 23
Issue 23 of Multiple Myeloma Research Review. Highlights include: • Revised Myeloma Comorbidity index for multiple myeloma prognosis. •...
Article of the week: Genetic changes associated with the evolution of Monoclonal Gammopathy of Unknown Significance (MGUS)
For this week's Article of the Week we have chosen a review article published in the British Journal of Haematology co-authored by MSAG member Dr...
Article of the week: Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease
For this week's Article of the Week we have chosen an article which is particularly relevant to the results of the recent VCAT study which is...
Article of the week: The use of sclerostin to increase bone mass and reduce the incidence of fractures in multiple myeloma
For this week's Article of the Week relates to a presentation made by Petere Croucher on the osteocyte-specific protein sclerostin at the most...
Article of the week: Letters to Blood – Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab
GarcÃa-Guerrero et al described their laboratory study where myeloma cells from 12 patients were treated with titrated doses of panobinostat (0, 10...
Expert Forum: Myeloma Summit August 2016
This publication is a summary of selected presentations delivered at the Haematology Society of Australia and New Zealand (HSANZ) Inaugural...
Newsletter: July 2017
Welcome to the first newsletter from Myeloma New Zealand. Setting up a new entity from scratch was always going to take time but we have made...
Research Review: Multiple Myeloma – Issue 22
Issue 22 of Multiple Myeloma Research Review. Highlights include: •  Benefits of low dose lenalidomide in relapsed/refractory MM. •  Network...
Article of the week: Phase 1b study of isatuximab plus lenalidomide and dexamethasone
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma'Â is a study intended to assess the...